Patents by Inventor Shinji Yata
Shinji Yata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120115827Abstract: The present invention relates to a novel 3-aminobenzamide, compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide, compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathicpain, rheumatoid arthritis pain, and neuralgia.Type: ApplicationFiled: June 7, 2011Publication date: May 10, 2012Applicant: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takashi Watanabe, Takuya Matsuo, Masahiro Sakata, Wataru Kondo
-
Patent number: 8153631Abstract: The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.Type: GrantFiled: November 19, 2009Date of Patent: April 10, 2012Assignee: Amgen Inc.Inventors: Jay P. Powers, Mario G. Cardozo, Hiroyuki Goto, Kazuhito Harada, Katsuaki Imamura, Makoto Kakutani, Isamu Matsuda, Yasuhiro Ohe, Shinji Yata
-
Publication number: 20110245223Abstract: The present invention provides a compound represented by the following formula [1?] or a salt thereof: wherein ring A, R2, R3, R4 and X are as defined in the description, and an agent for the treatment or prophylaxis of a pathology involving glucocorticoid, or a 11?HSD1 inhibitor, containing the compound or a salt thereof.Type: ApplicationFiled: December 1, 2010Publication date: October 6, 2011Applicant: Japan Tobacco Inc.Inventors: Hiroshi Yamamoto, Yasuhiro Ohe, Hiroyuki Goto, Kazuhito Harada, Shinji Yata, Takashi Ito, Jun Nishiu, Makoto Kakutani, Shunsuke Fujii, Kota Asahina
-
Publication number: 20110212952Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.Type: ApplicationFiled: February 1, 2011Publication date: September 1, 2011Applicant: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takayuki Yamasaki, Tatsuya Matsumoto, Masahiro Sakata, Wataru Kondo, Yoshikazu Hori
-
Patent number: 8008292Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.Type: GrantFiled: July 15, 2005Date of Patent: August 30, 2011Assignee: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takashi Watanabe, Takuya Matsuo, Takayuki Yamasaki, Masahiro Sakata, Wataru Kondo, Hidekazu Ozeki, Yoshikazu Hori
-
Patent number: 7906508Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.Type: GrantFiled: December 28, 2006Date of Patent: March 15, 2011Assignee: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takayuki Yamasaki, Tatsuya Matsumoto, Masahiro Sakata, Wataru Kondo, Yoshikazu Hori
-
Patent number: 7683059Abstract: The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome.Type: GrantFiled: September 5, 2006Date of Patent: March 23, 2010Assignee: Amgen Inc.Inventors: Mario G. Cardozo, Jay P. Powers, Hiroyuki Goto, Kazuhito Harada, Katsuaki Imamura, Makoto Kakutani, Isamu Matsuda, Yasuhiro Ohe, Shinji Yata
-
Publication number: 20100062972Abstract: The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.Type: ApplicationFiled: November 19, 2009Publication date: March 11, 2010Inventors: JAY P. POWERS, Mario G. CARDOZO, Hiroyuki GOTO, Kazuhito HARADA, Katsuaki IMAMURA, Makoto KAKUTANI, Isamu MATSUDA, Yasuhiro OHE, Shinji YATA
-
Publication number: 20100022523Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.Type: ApplicationFiled: April 27, 2009Publication date: January 28, 2010Applicant: Japan Tobacco Inc.Inventors: YOSHIHISA KOGA, SHINJI YATA, TAKASHI WATANABE, TAKUYA MATSUO, MASAHIRO SAKATA, WATARU KONDO
-
Publication number: 20080249084Abstract: The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome.Type: ApplicationFiled: October 27, 2004Publication date: October 9, 2008Inventors: Jay P. Powers, Mario G. Cardozo, Hiroyuki Goto, Kazuhito Harada, Katsuaki Imamura, Makoto Kakutani, Isamu Matsuda, Yasuhiro Ohe, Shinji Yata
-
Publication number: 20080161374Abstract: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.Type: ApplicationFiled: February 14, 2008Publication date: July 3, 2008Inventors: Hiroyuki Goto, Makoto Kakutani, Jun Nishiu, Yasuhiro Ohe, Jay P. Powers, Shinji Yata, Hua Tu
-
Patent number: 7354938Abstract: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.Type: GrantFiled: March 18, 2005Date of Patent: April 8, 2008Assignee: Amgen Inc.Inventors: Hiroyuki Goto, Makoto Kakutani, Jun Nishiu, Yasuhiro Ohe, Jay P. Powers, Shinji Yata, Hua Tu
-
Publication number: 20070149517Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.Type: ApplicationFiled: December 28, 2006Publication date: June 28, 2007Applicant: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takayuki Yamasaki, Tatsuya Matsumoto, Masahiro Sakata, Wataru Kondo, Yoshikazu Hori
-
Publication number: 20070072908Abstract: The present invention provides a compound represented by the following formula [1?] or a salt thereof: wherein ring A, R2, R3, R4 and X are as defined in the description, and an agent for the treatment or prophylaxis of a pathology involving glucocorticoid, or a 11?HSD1 inhibitor, containing the compound or a salt thereof.Type: ApplicationFiled: June 8, 2006Publication date: March 29, 2007Applicant: JAPAN TOBACCO INC.Inventors: Hiroshi Yamamoto, Yasuhiro Ohe, Hiroyuki Goto, Kazuhito Harada, Shinji Yata, Takashi Ito, Jun Nishiu, Makoto Kakutani, Shunsuke Fujii, Kota Asahina
-
Publication number: 20060035882Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.Type: ApplicationFiled: July 15, 2005Publication date: February 16, 2006Applicant: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takashi Watanabe, Takuya Matsuo, Takayuki Yamasaki, Masahiro Sakata, Wataru Kondo, Hidekazu Ozeki, Yoshikazu Hori
-
Publication number: 20060035939Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.Type: ApplicationFiled: July 14, 2005Publication date: February 16, 2006Applicant: Japan Tobacco Inc.Inventors: Yoshihisa Koga, Shinji Yata, Takashi Watanabe, Takuya Matsuo, Masahiro Sakata, Wataru Kondo
-
Publication number: 20050272793Abstract: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.Type: ApplicationFiled: March 18, 2005Publication date: December 8, 2005Applicant: Amgen Inc.Inventors: Hiroyuki Goto, Makoto Kakutani, Jun Nishiu, Yasuhiro Ohe, Jay Powers, Shinji Yata
-
Patent number: 5536737Abstract: Compounds of the formula ##STR1## wherein R is a hydrogen atom or an acyl; U is --O--, --CHR.sup.1 -- or --NR.sup.2 -- wherein R.sup.1 is a hydrogen atom or a hetero ring, and R.sup.2 is a hydrogen atom or a lower alkoxycarbonyl lower alkyl; V is --O--, --S--, --CHR.sup.3 -- or --NR.sup.4 -- wherein R.sup.3 is a hydrogen atom or a lower alkoxycarbonyl, and R.sup.4 is a hydrogen atom, a lower alkyl or an acyl; W is methyl, a hetero ring or optionally substituted phenyl; X and Y are the same or different and each is --CH.sub.2 -- or --S--; m is an integer of 0 to 6; and n is an integer of 1 to 4, and pharmaceutically acceptable salts thereof.The compounds of the present invention have specifically strong inhibitory activity against prolyl endopeptidase, and suppress decomposition and inactivation of TRH, substance P, neurotensin, vasopressin and the like. Accordingly, the compounds can be used for the prophylaxis and/or treatment of dementia and amnesia including Alzheimer's disease.Type: GrantFiled: May 24, 1995Date of Patent: July 16, 1996Assignee: Japan Tobacco Inc.Inventors: Koji Kobayashi, Minoru Akamatsu, Shinji Yata, Hiroyuki Abe, Katsuo Toide, Motohiro Kogayu, Itsuo Uchida